We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Simple Measurement Predicts Risk of Rapid Progression of Chronic Kidney Disease

By LabMedica International staff writers
Posted on 27 Feb 2024

Chronic kidney disease (CKD) is increasingly becoming a major health issue worldwide. More...

For those diagnosed with CKD, the rate of disease progression can vary, with some individuals experiencing a rapid deterioration in kidney function. Healthcare providers need to spot patients who are newly diagnosed with CKD and are at a heightened risk of rapid disease progression. Early identification can allow for timely interventions that could slow down, or in some cases, prevent the progression of the disease. Now, researchers have made a breakthrough by discovering a simple method to identify individuals at high risk for rapid CKD progression, an advancement that could greatly enhance prevention and treatment strategies.

In a comprehensive study, a team of researchers from Aarhus University (Aarhus, Denmark) examined the precise risk of rapid CKD progression utilizing data from Danish health registers. This study provides valuable insights for medical professionals on identifying patients who are more likely to experience a rapid deterioration of their kidney health. The study’s findings revealed that patients who have been recently diagnosed with mild to moderate CKD face a 15% chance of rapid disease progression within three years, a situation that could lead to severe cardiovascular issues or even be life-threatening. Interestingly, the study also uncovered considerable variation in the progression risk among different patients. A simple urine test to measure protein levels emerged as a key predictor of kidney disease trajectory.

For women who do not have diabetes, elevated blood pressure/cardiovascular disease, and lack albumin in their urine, the risk of rapid CKD progression stands at 7%. Conversely, the risk escalates to 47% for men who have both diabetes and elevated blood pressure/cardiovascular disease, along with the presence of albumin in their urine. This finding is critical as albumin can act as a marker for kidney disease progression. It enables the identification of patients who are most susceptible to rapid disease deterioration, thereby aiding in the prevention of complications and potentially enhancing the patient's quality of life. This finding highlights the importance of the widespread adoption of this simple urine test. By doing so, healthcare professionals can more effectively tailor treatments and monitoring for those at the greatest risk. This approach holds the potential for substantial benefits for patients globally.

"We hope that this result can contribute to increased awareness of the importance of using readily available markers – including albumin in the urine – to identify patients at high risk of rapid progression," said Christian Fynbo Christiansen, Professor at the Department of Clinical Medicine at Aarhus University. "I think we will focus much more in the future on patients with milder stages of the disease, like those we included in this study. If we get better at preventing and treating chronic kidney disease and its associated complications, it could potentially benefit both patients and society."

Related Links:
Aarhus University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Hematology Consumables
Bioblood Devices
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.